<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="letter">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">z6WQvzr4vNdh4dPXKyDwjRR</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2012000300012</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(12)09800312</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2012000300012</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Carta ao Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A polival&#234;ncia da prote&#237;na C reativa na revasculariza&#231;&#227;o mioc&#225;rdica</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Zanettini</surname>
            <given-names>Marco T&#250;lio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zanettini</surname>
            <given-names>Jacira Pisani</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zanettini</surname>
            <given-names>Jo&#227;o Ot&#225;vio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Caxias do Sul</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <institution content-type="orgname">Eletrocor Laborat&#243;rio C&#225;rdio-Diagn&#243;stico</institution>
        <country country="BR">Brasil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>03</month>
        <year>2012</year>
      </pub-date>
      <volume>98</volume>
      <issue>3</issue>
      <fpage>278</fpage>
      <lpage>279</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <pub-date publication-format="electronic" date-type="pub">
        <day>23</day>
        <month>04</month>
        <year>2012</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>CARTA AO EDITOR</bold>
    </p>
    <p>
      <bold>A polival&#234;ncia da prote&#237;na C reativa na revasculariza&#231;&#227;o mioc&#225;rdica</bold>
    </p>
    <p>
      <bold>Marco T&#250;lio Zanettini; Jacira Pisani Zanettini; Jo&#227;o Ot&#225;vio Zanettini</bold>
    </p>
    <p>Eletrocor Laborat&#243;rio C&#225;rdio-Diagn&#243;stico, Caxias do Sul, RS - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="not">Correspond&#234;ncia</xref>
    </p>
    <p><bold>Palavras-chave:</bold> Prote&#237;na C reativa, revasculariza&#231;&#227;o mioc&#225;rdica, cuidados pr&#233;-operat&#243;rios </p>
    <p>
      <bold>Caro Editor,</bold>
    </p>
    <p>Parabenizamos Mezzomo e colaboradores<sup>1</sup> pela extensa pesquisa realizada com dados de um centro terci&#225;rio de cardiologia correlacionando n&#237;veis elevados de prote&#237;na C reativa ultrassens&#237;vel (PCRus) e complica&#231;&#245;es p&#243;s-operat&#243;rias de cirurgia de revasculariza&#231;&#227;o mioc&#225;rdica (CRM).</p>
    <p>As evid&#234;ncias atuais mostram associa&#231;&#227;o independente entre doen&#231;a cardiovascular e eventos cardiovasculares maiores com n&#237;veis elevados de PCRus bem como redu&#231;&#227;o deste marcador inflamat&#243;rio e dos desfechos associados atrav&#233;s da utiliza&#231;&#227;o das estatinas<sup>2-4</sup>.</p>
    <p>Assim, neste estudo, a PCRus realmente p&#244;de predizer infec&#231;&#227;o respirat&#243;ria no p&#243;s-operat&#243;rio de CRM a despeito da falta de ajuste para classe funcional, fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo e uso de estatinas?</p>
    <p>
      <bold>Carta-resposta</bold>
    </p>
    <p>Agradecemos os coment&#225;rios pertinentes em rela&#231;&#227;o ao nosso artigo, o que ressalta a import&#226;ncia e atualidade do tema.</p>
    <p>A PCR &#233; um marcador biol&#243;gico que vem sendo estudado nas &#250;ltimas d&#233;cadas como um mediador de aterosclerose, assim como um preditor de condi&#231;&#227;o inflamat&#243;ria<sup>1</sup>. Visto que as estatinas t&#234;m um importante papel na prote&#231;&#227;o e combate &#224; inflama&#231;&#227;o, &#233; relevante pensar que o seu uso no per&#237;odo pr&#233;-operat&#243;rio de revasculariza&#231;&#227;o mioc&#225;rdica reduza a PCR, e consequentemente as complica&#231;&#245;es deste procedimento. Estudos j&#225; citados no artigo, como o realizado por Clark e Vaduganathan<sup>2,3</sup>, demonstraram que o uso de estatina no pr&#233;-operat&#243;rio reduziu a morbimortalidade no p&#243;s-operat&#243;rio. J&#225; Mannancio e cols.<sup>4</sup> em 2010, demonstraram apenas redu&#231;&#227;o de dano mioc&#225;rdico, sem ser significativo para mortalidade. </p>
    <p>No nosso estudo, os pacientes em uso de estatina apresentaram PCR inferior a 3 mg/l em 73% dos casos contra 59,7% com PCRus &gt; 3mg/l (p = 0,013). No entanto, em an&#225;lise multivariada com os desfechos cl&#237;nicos de maior incid&#234;ncia, como fibrila&#231;&#227;o atrial e infec&#231;&#245;es, n&#227;o foi observada prote&#231;&#227;o, em compara&#231;&#227;o aos que n&#227;o utilizavam estatina<sup>5</sup>.</p>
    <p>Com rela&#231;&#227;o &#224; classe funcional, foram exclu&#237;dos do estudo os pacientes com FE &lt; 30% e em classe funcional IV, sendo estes os pacientes de maior morbimortalidade na revasculariza&#231;&#227;o mioc&#225;rdica. Os pacientes com disfun&#231;&#227;o sist&#243;lica leve a moderada n&#227;o foram discriminados. Tendo em vista que somente 54% da amostra tinham esse dado coletado, n&#227;o foi poss&#237;vel controlar para a Fra&#231;&#227;o de Eje&#231;&#227;o do Ventr&#237;culo Esquerdo<sup>5</sup>. </p>
    <p>Concluindo, a PCRus foi preditora de infec&#231;&#227;o respirat&#243;ria, nesta amostra. O ajuste foi feito para as principais vari&#225;veis (aquelas com valor de p &lt; 0,20 na an&#225;lise bivari&#225;vel) ou que poderiam aumentar o risco de infec&#231;&#227;o respirat&#243;ria, tais como: idade avan&#231;ada, tabagismo, diabetes, DPOC, obesidade e dura&#231;&#227;o da ventila&#231;&#227;o mec&#226;nica<sup>5</sup>.</p>
    <p>
      <bold>Refer&#234;ncias (Resposta)</bold>
    </p>
    <p>
      <fn id="not" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Marco T&#250;lio Zanettini </p>
        <p> Olinto Mario Luchese, 318 - Santa Catarina </p>
        <p> 95032-250 - Caxias do Sul, RS - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="marcotz@eletrocorcardiologia.com.br">marcotz@eletrocorcardiologia.com.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 05/11/11; revisado recebido em 05/11/11; aceito em 20/12/11.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Mezzomo A, Bordin J&#250;nior OL, Portal VL. Prote&#237;na C Reativa pr&#233;-operat&#243;ria prediz infec&#231;&#227;o respirat&#243;ria ap&#243;s cirurgia de revasculariza&#231;&#227;o mioc&#225;rdica. Arq Bras Cardiol. 2011;97(5):365-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prote&#237;na C Reativa pr&#233;-operat&#243;ria prediz infec&#231;&#227;o respirat&#243;ria ap&#243;s cirurgia de revasculariza&#231;&#227;o mioc&#225;rdica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2011</year>
          </date>
          <fpage>365</fpage>
          <lpage>71</lpage>
          <issue>5</issue>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mezzomo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bordin J&#250;nior</surname>
              <given-names>OL</given-names>
            </name>
            <name>
              <surname>Portal</surname>
              <given-names>VL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G, et al. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89(8):901-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>901</fpage>
          <lpage>8</lpage>
          <issue>8</issue>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bickel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rupprecht</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Blankenberg</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Espiniola-Klein</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schlitt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rippin</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Vaduganathan M, Stone NJ, Lee R, McGee EC Jr, Malaisrie SC, Silverberg RA, et al. Perioperative statin therapy reduces mortality in normolipidemic patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2010;140(5):1018-27.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Perioperative statin therapy reduces mortality in normolipidemic patients undergoing cardiac surgery</article-title>
          <source>J Thorac Cardiovasc Surg</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>1018</fpage>
          <lpage>27</lpage>
          <issue>5</issue>
          <volume>140</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Vaduganathan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>McGee Jr</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Malaisrie</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Silverberg</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Mannacio VA, Iorio D, DeAmicis V, Di Lello F, Musumeci F. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg. 2010;136(6):1541-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial</article-title>
          <source>J Thorac Cardiovasc Surg</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>1541</fpage>
          <lpage>8</lpage>
          <issue>6</issue>
          <volume>136</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mannacio</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Iorio</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>DeAmicis</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Di Lello</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Musumeci</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>1. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation. 2003;108(16):1917-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>New markers of inflammation and endothelial cell activation: Part I</article-title>
          <source>Circulation</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1917</fpage>
          <lpage>23</lpage>
          <issue>16</issue>
          <volume>108</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Szmitko</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Weisel</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>de Almeida</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>2. Clark LL, Ikonomidis JS, Crawford FA Jr, Crumbley A 3<sup>rd</sup>, Kratz JM, Stroud MR, et al. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg. 2006;131(3):679-85.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study</article-title>
          <source>J Thorac Cardiovasc Surg</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>679</fpage>
          <lpage>85</lpage>
          <issue>3</issue>
          <volume>131</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Clark</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Ikonomidis</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Crawford Jr</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Crumbley 3rd</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kratz</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Stroud</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>3. Vaduganathan M, Stone NJ, Lee R, McGee EC Jr, Malaisrie SC, Silverberg RA, et al. Perioperative statin therapy reduces mortality in normolipidemic patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2010;140(5):1018-27.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Perioperative statin therapy reduces mortality in normolipidemic patients undergoing cardiac surgery</article-title>
          <source>J Thorac Cardiovasc Surg</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>1018</fpage>
          <lpage>27</lpage>
          <issue>5</issue>
          <volume>140</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Vaduganathan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>McGee Jr</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Malaisrie</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Silverberg</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>4. Mannacio VA, Iorio D, DeAmicis V, Di Lello F, Musumeci F. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg. 2010;136(6):1541-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial</article-title>
          <source>J Thorac Cardiovasc Surg</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>1541</fpage>
          <lpage>8</lpage>
          <issue>6</issue>
          <volume>136</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mannacio</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Iorio</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>DeAmicis</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Di Lello</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Musumeci</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>5. Mezzomo A, Bordin J&#250;nior OL, Portal VL. Prote&#237;na C Reativa pr&#233;-operat&#243;ria prediz infec&#231;&#227;o respirat&#243;ria ap&#243;s cirurgia de revasculariza&#231;&#227;o mioc&#225;rdica. Arq Bras Cardiol. 2011;97(5):365-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prote&#237;na C Reativa pr&#233;-operat&#243;ria prediz infec&#231;&#227;o respirat&#243;ria ap&#243;s cirurgia de revasculariza&#231;&#227;o mioc&#225;rdica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2011</year>
          </date>
          <fpage>365</fpage>
          <lpage>71</lpage>
          <issue>5</issue>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mezzomo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bordin J&#250;nior</surname>
              <given-names>OL</given-names>
            </name>
            <name>
              <surname>Portal</surname>
              <given-names>VL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">La polivalencia de la prote&#237;na C reactiva en la revascularizaci&#243;n mioc&#225;rdica</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>
        <bold>CARTA AL EDITOR</bold>
      </p>
      <p>
        <fn id="inicio-body2">
          <label>
            <bold>La polivalencia de la prote&#237;na C reactiva en la revascularizaci&#243;n mioc&#225;rdica</bold>
          </label>
          <p>
            <bold>Marco T&#250;lio Zanettini; Jacira Pisani Zanettini; Jo&#227;o Ot&#225;vio Zanettini</bold>
          </p>
        </fn>
      </p>
      <p>Eletrocor Laborat&#243;rio C&#225;rdio-Diagn&#243;stico, Caxias do Sul, RS - Brasil</p>
      <p>Correspondencia</p>
      <p><bold>Palabras clave:</bold> Prote&#237;na C reactiva, revascularizaci&#243;n mioc&#225;rdica, cuidados preoperatorios</p>
      <p>
        <bold>Estimado Editor,</bold>
      </p>
      <p>Felicitamos a Mezzomo et al<sup>1</sup> por su extensa investigaci&#243;n realizada con los datos de un centro terciario de cardiolog&#237;a correlacionando niveles elevados de prote&#237;na C Reactiva ultrasensible (PCRus), y complicaciones postoperatorias de cirug&#237;a de revascularizaci&#243;n mioc&#225;rdica (CRM).</p>
      <p>Las evidencias actuales demuestran una asociaci&#243;n independiente entre la enfermedad cardiovascular y los eventos cardiovasculares mayores con niveles elevados de PCRus, como tambi&#233;n una reducci&#243;n de ese marcador inflamatorio y de los resultados asociados a trav&#233;s de la utilizaci&#243;n de las estatinas<sup>2-4</sup>.</p>
      <p>Por tanto, en ese estudio, &#191;la PCRus realmente pudo predecir la infecci&#243;n respiratoria en el postoperatorio de CRM pese a la falta de un ajuste para la clase funcional, fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo y uso de estatinas?</p>
      <p>
        <bold>Carta respuesta</bold>
      </p>
      <p>Le agradecemos sus comentarios pertinentes con relaci&#243;n a nuestro art&#237;culo, lo que resalta la importancia y la actualidad del tema.</p>
      <p>La PCR es un marcador biol&#243;gico que ha venido siendo estudiado en las &#250;ltimas d&#233;cadas como un mediador de arteriosclerosis, como tambi&#233;n un predictor de condici&#243;n inflamatoria<sup>1</sup>. Y ya que las estatinas poseen un importante papel en la protecci&#243;n y en el combate a la inflamaci&#243;n, es relevante pensar que su uso en el per&#237;odo del preoperatorio de revascularizaci&#243;n mioc&#225;rdica reduzca la PCR, y por ende, las complicaciones de ese procedimiento. Estudios que ya han sido citados en el art&#237;culo, como el realizado por Clark y Vaduganathan<sup>2,3</sup>, demostraron que el uso de la estatina en el preoperatorio redujo la morbimortalidad en el postoperatorio. En el 2010, Mannancio et al<sup>4</sup>, solamente demostraron una reducci&#243;n en el da&#241;o mioc&#225;rdico, sin que eso fuere significativo para la mortalidad.</p>
      <p>En nuestro estudio, los pacientes que usaban estatina presentaron PCR inferior a 3 mg/l en un 73% de los casos, contra un 59,7% con PCRus &gt; 3mg/l (p = 0,013). Sin embargo, en un an&#225;lisis multivariado con los resultados cl&#237;nicos de mayor incidencia, como la fibrilaci&#243;n atrial y las infecciones, no fue observada una protecci&#243;n en comparaci&#243;n con los que no utilizaban estatina<sup>5</sup>.</p>
      <p>Con relaci&#243;n a la clase funcional, quedaron excluidos del estudio los pacientes con FE &lt; 30% y en la clase funcional IV, siendo esos los pacientes de mayor morbimortalidad en la revascularizaci&#243;n mioc&#225;rdica. Los pacientes con disfunci&#243;n sist&#243;lica ligera a moderada no fueron estudiados. Teniendo en cuenta que solamente un 54% de la muestra ten&#237;an ese dato recolectado, no se pudo controlar para la Fracci&#243;n de Eyecci&#243;n del Ventr&#237;culo Izquierdo<sup>5</sup>.</p>
      <p>Como colof&#243;n, la PCRus fue la predictora de la infecci&#243;n respiratoria en esta muestra. El ajuste se hizo para las principales variables (aquellas con un valor de p &lt; 0,20 en el an&#225;lisis bivariable), o que podr&#237;an aumentar el riesgo de infecci&#243;n respiratoria, tales como: la edad avanzada, el tabaquismo, la diabetes, EPOC, obesidad y duraci&#243;n de la ventilaci&#243;n mec&#225;nica<sup>5</sup>.</p>
      <p>
        <bold>Referencias</bold>
      </p>
      <p>
        <bold>Refer&#234;ncias (Resposta)</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">The polyvalence of C-reactive protein in coronary artery bypass grafting</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>
        <bold>LETTER TO THE EDITOR</bold>
      </p>
      <p>
        <fn id="nota-body3">
          <label>
            <bold>The polyvalence of C-reactive protein in coronary artery bypass grafting</bold>
          </label>
          <p>
            <bold>Marco T&#250;lio Zanettini; Jacira Pisani Zanettini; Jo&#227;o Ot&#225;vio Zanettini</bold>
          </p>
        </fn>
      </p>
      <p>Eletrocor Laborat&#243;rio C&#225;rdio-Diagn&#243;stico, Caxias do Sul, RS - Brazil</p>
      <p>Mailing Address</p>
      <p><bold>Palavras-chave:</bold> Prote&#237;na C reativa, revasculariza&#231;&#227;o mioc&#225;rdica, cuidados pr&#233;-operat&#243;rios </p>
      <p>
        <bold>Dear Editor,</bold>
      </p>
      <p>We congratulate Mezzomo et al<sup>1</sup> for the thorough research based on data of a Tertiary Cardiology Center, correlating high levels of Ultra-sensitive C-Reactive Protein (us-CRP) and postoperative complications of Coronary Artery Bypass Grafting surgery (CABG).</p>
      <p>Current evidence reveals independent association between cardiovascular disease and major cardiovascular events with high levels of us-CRP, as well as the reduction of this inflammatory marker and the associated outcomes by administering statins<sup>2-4</sup>.</p>
      <p>Hence, in this study, were us-CRP's actually the predictors of respiratory infection in the CABG postoperative period, in spite of the lack of adjustment for functional classroom, left ventricular ejection fraction and administration of statins?</p>
      <p>
        <bold>Reply</bold>
      </p>
      <p>We would like to thank for the fitting remarks on this article, which underscore the relevance and prevalence of the subject.</p>
      <p>CRP is the biological marker which is being studied over the last few decades as an arteriosclerosis mediator, as well as a predictor for inflammatory disease<sup>1</sup>. Since statins play an important role in the protection and combat against inflammation, we believe to be important reflecting on its administration over the preoperative period of coronary artery bypass grafting as a way to reduce CRP and, consequently, on the complications of this procedure. The studies already referred to in this article, as the one performed by Clark and Vaduganathan<sup>2,3</sup>, have evidenced that the administration of statin in the preoperative period reduced the morbidity and mortality over the postoperative period. In his turn, Mannancio et al<sup>4</sup> in 2010, have shown only reduction in the myocardial damage, not impacting mortality significantly. </p>
      <p>In our study, patients receiving statin presented CRP lower than 3 mg/l in 73% of the cases versus 59.7% with us-CRP &gt; 3mg/l (p = 0.013). However, in multivariate analysis with the clinical outcomes of higher incidence, such as atrial fibrillation and infections, protection was not observed, compared to those which were not administered with statin<sup>5</sup>.</p>
      <p>Relating to the functional class, patients with EF &lt; 30% and in functional class IV were excluded from the study, and these patients presented higher morbidity and mortality in coronary artery bypass grafting. The patients with light to moderate systolic dysfunction have not been treated separately. Taking into consideration that only 54% of the sample only had this data collected, controlling the Left Ventricular Ejection Fraction was not possible<sup>5</sup>. </p>
      <p>In view of the above, we conclude that the us-CRP was predictor of respiratory infection in this sample. The adjustment was made for the main variables (those with p value &lt; 0.20 in the bivariate analysis) or the ones that could increase the risk of respiratory infection, such as: advanced age, tobacco addiction, diabetes, COPD, obesity and duration of mechanical ventilation<sup>5</sup>.</p>
      <p>
        <bold>References</bold>
      </p>
      <p>
        <bold>Refer&#234;ncias (Resposta)</bold>
      </p>
    </body>
  </sub-article>
</article>
